Takeaway
- GlycA level was associated with increased risk for all-cause mortality in both men and women and with a higher risk for cancer mortality in men only.
- However, GlycA and high-sensitivity C-reactive protein (hsCRP) levels were not independently associated with cardiovascular (CV) mortality.
Why this matters
- Previous studies have suggested that GlycA is associated with all-cause mortality in high-risk patients with established cardiovascular disease (CVD) or with several CV risk factors.
- Published studies on GlycA and all-cause mortality show variable effect sizes.
Study design
- 5526 patients who participated in the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) were included.
- The association of GlycA and hsCRP with all-cause, cancer and CV mortality was evaluated across sex-stratified quartile 1 (n=1387), 2 (n=1386), 3 (n=1373) and 4 (n=1380).
- Funding: None disclosed.
Key results
- After adjustment for confounders, GlycA was associated with increased risk for all-cause mortality (HR, 1.43; 95% CI, 1.09-1.87; P=.009) among top (1) vs bottom (4) quartile.
- No significant association was observed in hsCRP level and all-cause mortality (HR, 1.16; 95% CI, 0.88-1.51; P=.29).
- GlycA (HR, 1.55; 95% CI, 1.03-2.32; P=.034) and hsCRP (HR, 1.71; 95% CI, 1.12-2.61; P=.014) linked to increased risk for cancer mortality in men, but not in women.
- No significant association was observed between GlycA (HR, 1.05; 0.59-1.89; P=.88) and hsCRP (HR, 0.76; 95% CI, 0.45-1.30; P=.32) and CV mortality.
- In a meta-analysis of 7 studies, including 8153 deaths, GlycA was associated with higher risk for all-cause mortality (relative risk, 1.74; 95% CI, 1.40-2.17) in top vs bottom quartiles.
Limitations
- Findings were based on a single baseline measurement of hsCRP and GlycA.
- Study did not identify underlying causes.
References
References
